Effect of Aerosolised Colistin in Ventilator Associated Pneumonia
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
the management of Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR)
gram-negative bacilli (GNB) represent a real therapeutic dilemma in intensive care unit
(ICU). Colistin remains an effective agent against MDR GNB. However, because of its side
effects, mainly nephrotoxicity, other modalities than the intra venous (IV) route should be
tried. Several recent data emphasize the interest of inhaled route. The investigators purpose
was to evaluate the effectiveness and systemic toxicity of aerosolized colistin in ventilator
associated pneumonia.